



## COMPANY PROFILE

Response Biomedical develops, manufactures and markets rapid point-of-care (POC) diagnostic tests for use with our proprietary RAMP® (Rapid Analyte Measurement Platform) System for clinical and environmental applications. RAMP® has set a new performance standard in rapid diagnostic testing by providing lab quality information in minutes.

## GROWING THE COMPANY

We anticipate that the RAMP® System will establish a new performance standard in rapid clinical infectious diseases and cardiovascular testing worldwide.

### Cardiovascular.

Response Biomedical is focused on POC tests in the cardiovascular area.

### Strategic Alliance with Roche Diagnostics

In June 2008, we entered into an agreement with Roche Diagnostics, the largest *in vitro* diagnostics company in the world, to market our line of cardiovascular point-of-care tests worldwide.

The Company cardiovascular focus includes:

- **Cardiac Markers** – proteins released in the blood following a heart attack - Myoglobin, Troponin I and CK-MB are the three most commonly utilized markers measured to assist in the diagnosis of heart attack or acute myocardial infarction, a leading cause of death worldwide. We have regulatory clearance from the U.S. Food and Drug Administration (FDA) and Health Canada to market these tests to assist in the rapid diagnosis of heart attack or acute myocardial infarction.
- **Heart Failure (HF)** – According to the American Heart Association, approximately 5 million Americans are currently afflicted with HF and 550,000 new cases are diagnosed each year. NT-proBNP and BNP are widely recognized as definitive tests for diagnosing HF, with a market potential approaching USD 1.0 billion globally. HF affects nearly 17 million people worldwide, and is the single most frequent cause of hospitalization in people over 65.
  - **NT-proBNP** – We received a 510(k) clearance application from the FDA in July 2008 and Roche has now launched the product in the U.S., while we sell the product through a distributor arrangement in China Roche has introduced the cardiac products. Our next projects include a trial to obtain CLIA waiver for NT-proBNP and a next generation Troponin I redevelopment.
  - **BNP** – Our partner in Japan, Shionogi & Co. Ltd, successfully launched the RAMP® BNP Test for HF in Japan in Q3 2006, making RAMP® the only commercially available POC BNP test in the Japanese market.

**Strategic Alliance with 3M.** We have also formed a strategic alliance with 3M to co-develop our infectious diseases line of products, globally. Our current focus is:

- **Flu A+B** – We have developed a high sensitivity rapid test for detecting influenza A and B (Flu A+B), a highly contagious disease caused by the influenza virus that attacks the respiratory tract in humans. We have shown that we are capable of producing highly sensitive and reliable information with significant performance improvements over established rapid immunoassays. 3M launched the product in October 2008 in the U.S. The product is also cleared in Canada.
- **RSV** – The RSV test manufactured by Response Biomedical runs on the RAMP® 200 Reader and will be marketed and sold by 3M Health Care as the 3M™ Rapid Detection RSV Test. The test detects the presence of RSV F-protein antigens in nasopharyngeal swab, nasopharyngeal aspirate, or nasal wash/aspirate specimens. Measurement of RSV aids in the rapid diagnosis of RSV viral infections in symptomatic patients. The test has a 510(K) clearance from the FDA and has been launched in the U.S.

## CORPORATE HIGHLIGHTS

- 11/01/2010** RBM Pre-Announces Record Revenues for 2010 – Approximately \$10 Million
- 22/10/2009** RBM Obtains Special 510(k) U.S. FDA Clearance to Add Analytical Reactivity Information for the 2009 H1N1 Influenza A Virus to RAMP® Influenza A/B Assay Package Insert
- 29/07/2009** RBM Receives U.S. FDA 510(k) Market Clearance for RSV Test
- 20/04/2009** RBM Delivers Record Preliminary Revenues in First Quarter – Revenues Grow 115% Over Q1/2008
- 12/02/2009** RBM Announces Funded Development Program with Roche to Expand Cardiovascular Product Offerings

## NEAR TERM MILESTONES/Next Steps

- Complete Troponin I redevelopment
- CLIA-Waiver – NT-proBNP
- Pursue other clinical diagnostic partnerships
- New assay development
- Expand commercial opportunities in Asia



# The RAMP® System

CARDIOVASCULAR DISEASE


INFECTIOUS DISEASES

BIODEFENSE

WEST NILE VIRUS



The RAMP® System – consists of a portable fluorescent Reader and single use, disposable test cartridges. This proprietary diagnostic platform delivers highly sensitive, reliable results in less than 15 minutes, and has the potential to be applied to more than 250 medical and non-medical tests currently performed in laboratories.



*Our corporate values are built on a foundation of communication and teamwork*

## SENIOR MANAGEMENT

**S. Wayne Kay**  
Chief Executive Officer  
**Duane Morris**  
Chief Operating Officer

**Livleen Kaler**  
Vice President Finance & Administration and  
Chief Financial Officer  
**Paul Harris**  
Vice President Research and Development  
**Patricia Massitti**  
Director, Human Resources

## TOP INSTITUTIONAL HOLDINGS

- o Beutel, Goodman and Co. Ltd
- o 3M Corporation

## CONTACT

**Bill Wickson**  
Response Biomedical Corporation  
Director, Investor Relations  
1781-75<sup>th</sup> Avenue W.  
Vancouver, BC Canada V6P 6P2

[bwickson@responsebio.com](mailto:bwickson@responsebio.com)  
Phone: 604-456-6073  
1-888-591-5577 Ext. 6073